We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pfizer Acquires COVID-Flu Test Developer Lucira Health for USD 36.4 Million

By LabMedica International staff writers
Posted on 02 May 2023

Pfizer Inc. (New York, NY, USA) has acquired Lucira Health, Inc. (Emeryville, CA, USA) for USD 36.4 million in a bankruptcy auction.

Lucira filed for bankruptcy in February 2023, just two days before receiving FDA Emergency Use Authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test capable of differentiating and detecting influenza A and B. The COVID-19 & Flu Home Test is a single-use at-home test kit that delivers results from self-collected nasal swab samples in about 30 minutes. Lucira had previously received the first FDA EUA for an at-home rapid self-test, the Lucira COVID-19 All-in-One Test Kit, in November 2020, and the company announced in April 2021 that it had secured OTC EUA for its Lucira Check It test kit for SARS-CoV-2. The company's tests use a handheld battery-powered real-time testing instrument with nasal swab samples and loop-mediated isothermal amplification to provide results in 30 minutes. In November 2022, the FDA granted the company EUA for point-of-care use of its RT-LAMP-based COVID-19 and flu test.


Image: The Lucira COVID-19 Test provides 98% accurate, lab-quality results in 30 minutes or less (Photo courtesy of Lucira)
Image: The Lucira COVID-19 Test provides 98% accurate, lab-quality results in 30 minutes or less (Photo courtesy of Lucira)

During the COVID-19 pandemic, Lucira experienced rapid growth as demand for the company's COVID-19 test kits increased. When announcing its Chapter 11 plans, Lucira stated that a lengthy EUA process for its COVID-19 and influenza test had proved expensive, leading to the bankruptcy filing and sale process. Lucira also mentioned in a previous SEC filing that a lack of clinical data had forced the company to restrict its combination test to point-of-care use until it could obtain more prospective clinical data.

Related Links:
Pfizer Inc. 
Lucira Health, Inc.


New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit
New
Urine Strips
11 Parameter Urine Strips

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests